Humira Cost by Country 2025

Humira is a medication that is used to treat pain and swelling that is caused by various types of arthritis, including rheumatoid, psoriatic, and more. There are also certain skin disorders that the medication can help treat. In this article, we will learn more about how much Humira is costing those who trust it for their pain management needs.

Currently, the country that has the highest price for Humira is the United States. If you purchase the medication in the US, you can expect to pay an average of $4,000 or more. Prices in the US for Humira have steadily increased over the years. In 2015, the average price was $3,431, but by 2017, the average price was $4,480.

At some point in 2023, it is expected that an alternative to Humira will hit the market, which could help drive costs lower again. However, these new medications are still pending FDA approvals and necessary applications, so it is uncertain when those who rely on Humira may be able to purchase them and see some cost savings.

As of 2017, many countries around the world offered the medication at much lower prices than the United States. For example, residents of the United Arab Emirates could purchase the medication at an average price of $1,970. German residents had access to Humira at an average price of $1,570 in 2017. While still over $1,000, Switzerland’s price for Humira was also significantly lower than that of the US in 2017. In this country, you could purchase the drug for an average cost of $1,570.

Some countries even had Humira prices lower than $1,000 in 2017. Those living in the Netherlands had the option to buy the prescription for around $780, for example. The United Kingdom had slightly higher average prices at $860 and South Africa offered the prescription at an average price of $740. South Africa also had the lowest price for Humira in 2015. Then, you could purchase the prescription for an impressive $570. However, as with the other countries, price increases were seen around the board over the last several years.

2023 is a volatile market for Humira because patents are running out for the prescription in October. That means more competitors will be able to venture into the pain relief market and begin offering similar prescriptions at improved prices. This should begin affecting the prices of Humira around the world within the coming months.